The referral of a patient with features of Cushing's syndrome but with suppressed plasma cortisol and adrenocorticotrophic hormone concentrations prompted us to study the effect of medroxyprogesterone acetate (MPA) therapy on the adrenal axis. 11 women (aged 54–82 years) who were receiving 200–400 mg/day MPA were studied. Of these, four had subnormal plasma cortisol responses to a short synacthen test, and two more had borderline responses (30 min post-synacthen plasma cortisol results of 411 and 511 nmol/L). We conclude that suppression of the adrenal axis occurs relatively frequently in patients on MPA and that such patients should be checked for evidence of suppression before MPA therapy is withdrawn.
SiminoskiKGossPDruckerD.The Cushing syndrome induced by medroxyprogesterone acetate. Ann Intern Med.1989; 111: 758–60.
2.
DonckierJEMichelLABuysschaertM.Cushing syndrome and medroxyprogesterone acetate. Lancet1990; 335: 1094.
3.
GrenfellARudenskiAWattsMWiltshireCDayJLGrayIP.Cushing's syndrome and medroxyprogesterone acetate. Lancet1990; ii: 256.
4.
MerrinPAlexanderWD.Cushing's induced by medroxyprogesterone. BMJ1990; 301: 345.
5.
GlennEMRichardsonSLBowmanBJ.Biologic activity of 6 alpha-methyl compounds corresponding to progesterone, 17 alpha hydroxyprogesterone acetate and Compound S. Metabolism1959; 8: 265–85.
6.
GuthrieGPJohnWJ.The in vivo glucocorticoid and antiglucocorticoid actions of medroxyprogesterone acetate. Endocrinology1980; 107: 1393–6.
7.
KontulaKPaavonenTLuukkainenTAnderssonLC.Binding of progestins to the glucocorticoid receptor: correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes. Biochem Pharmacol1983; 32: 1511–18.
8.
LundbladJRRobertsJ.Regulation of proopiomelanocortin gene expression in pituitary. Endocrine Rev.1989; 9: 135–58.
9.
CamanniFMassaraFMolinattiGM.The cortisone-like effect of 6α-methyl-17α-acetoxy progesterone in the adrenalactomized man. Acta Endocrinol1963; 43: 477–83.
10.
MatthewsJHAbramsCALMorishimaA.Pituitary-adrenal function in ten patients receiving medroxyprogesterone acetate for true precocious puberty. J Clin Endocrinol Metab1970; 30: 653–8.
11.
SadoffLLuskW.The effect of large doses of medroxyprogesterone acetate (MPA) on urinary oestrogen levels and serum levels of cortisol T4, LH and testosterone in patients with advanced cancer. Obstet Gynecol1973; 43: 262–7.
12.
HellmanLYoshidaKZumoffBLevinJKleanJFukushimaD.The effect of medroxyprogesterone acetate on the pituitary-adrenal axis. J Clin Endocrinol Metab1976; 42: 912–16.
13.
LeisDBottermanPErmlerRHenderkottHGluckH.The influence of high doses of oral medroxyprogesterone acetate on glucose tolerance, serum insulin levels and adrenal response to ACTH. Arch Gynecol1980; 230: 9–13.
14.
PannutiFFonetFPiahaE.The anabolic effect induced by high doses of medroxyprogesterone acetate (MPA) orally in cancer patients. IRCS Med Sci.1978; 6: 118.
